- Home
- INVE vs MDXH Comparison
INVE vs MDXH Comparison
Compare INVE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- MDXH
- Stock Information
- Founded
- INVE 1990
- MDXH 2003
- Country
- INVE United States
- MDXH Belgium
- Employees
- INVE N/A
- MDXH N/A
- Industry
- INVE Computer peripheral equipment
- MDXH
- Sector
- INVE Technology
- MDXH
- Exchange
- INVE Nasdaq
- MDXH Nasdaq
- Market Cap
- INVE 74.2M
- MDXH 84.6M
- IPO Year
- INVE 1997
- MDXH 2021
- Fundamental
- Price
- INVE $3.24
- MDXH $2.18
- Analyst Decision
- INVE Strong Buy
- MDXH Buy
- Analyst Count
- INVE 3
- MDXH 1
- Target Price
- INVE $6.50
- MDXH $6.00
- AVG Volume (30 Days)
- INVE 69.3K
- MDXH 67.7K
- Earning Date
- INVE 08-07-2025
- MDXH 08-20-2025
- Dividend Yield
- INVE N/A
- MDXH N/A
- EPS Growth
- INVE N/A
- MDXH N/A
- EPS
- INVE 3.12
- MDXH N/A
- Revenue
- INVE $25,239,000.00
- MDXH $94,507,000.00
- Revenue This Year
- INVE N/A
- MDXH $23.51
- Revenue Next Year
- INVE $9.00
- MDXH $17.68
- P/E Ratio
- INVE $1.04
- MDXH N/A
- Revenue Growth
- INVE N/A
- MDXH 25.46
- 52 Week Low
- INVE $2.86
- MDXH $1.35
- 52 Week High
- INVE $4.35
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- INVE 49.66
- MDXH 56.42
- Support Level
- INVE $3.10
- MDXH $2.12
- Resistance Level
- INVE $3.25
- MDXH $2.32
- Average True Range (ATR)
- INVE 0.11
- MDXH 0.12
- MACD
- INVE -0.00
- MDXH 0.00
- Stochastic Oscillator
- INVE 55.00
- MDXH 73.33
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.